Taken together, HER2+ breast tumours are composed of (sub)clonal clusters of mutations which are established in therapy naïve tumours, maintained through treatment and may be associated with poor neoadjuvant therapy response. The gene discussed is ERBB2; the disease is breast neoplasm.